? SHARED RESOURCES MANAGEMENT The Ohio State University Comprehensive Cancer Center (OSUCCC) manages and supports 16 CCSG-funded Shared Resources (SRs) and is proposing two developing shared resources in this application. The goals of the OSUCCC SRs are to support OSUCCC members by providing specialized technologies, services, and expertise that maximize quality and speed of service, while maintaining cost-effectiveness and quality control. The SRs support all five Research Programs and are managed by faculty from seven different colleges and Nationwide Children?s Hospital. Most of the SRs are centrally located and in close proximity to OSUCCC members.
The Specific Aims for Shared Resource Management are to: 1) evaluate for need, and establish new specialized technologies, services and expertise that enhance scientific interaction and productivity; 2) ensure that the SRs provide cost-effective, reliable, and quality-controlled technologies, services and expertise; 3) support SRs through budget planning, laboratory management systems, and sustainability; and 4) establish policies for SR access and use. The OSUCCC directly manages 13 of the 16 SRs, and the others are jointly managed as institutional SRs that follow NCI policies. Reporting to the OSUCCC Director, the SRs are led by Sharyn Baker, PharmD, PhD, Associate Director for Shared Resources. Dr. Baker works with Heather Hampel MS, LGC, Associate Director for Biospecimen Research for integration of biospecimen services with the SRs. Dr. Baker leads the Shared Resource Team Leader (SRTL) committee that oversees SR management and implementation of the scientific vision. The SRTL monitors quality and user satisfaction through user surveys and user committees. SR development and evaluation is provided to Dr. Baker from the Associate Directors Committee, Program Leaders, and the External Scientific Advisory Board. Shared Resource Management operations include ensuring compliance with OSUCCC policies (prioritization of use and access, budgets, billing, and quality control) and compliance with OSU Office of Research policies and the federal Uniform Guidance. For the evaluation of new instrumentation and services, Dr. Baker manages the Intramural Research Program (IRP) that provides external peer review of SR applications, evaluating scientific merit and planned usage ($3.4M awarded this grant cycle. Overall support to the SRs over the last grant cycle has been $18M, allowing for all of the SRs to have been enhanced and offer new services. Future plans for each SR are accounting for planned increased usage due to the OSUCCC strategic research priorities and planned recruitment. The OSUCCC provides over $9M in overall support of the SRs annually, The OSUCCC is requesting a total of $1,971,340 in CCSG funding, 8.9% of the total support.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090000
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Kelly, Rachel S; Lasky-Su, Jessica; Yeung, Sai-Ching J et al. (2018) Integrative omics to detect bacteremia in patients with febrile neutropenia. PLoS One 13:e0197049
Straus, David J; Jung, Sin-Ho; Pitcher, Brandelyn et al. (2018) CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. Blood 132:1013-1021
Kim, Yangjin; Yoo, Ji Young; Lee, Tae Jin et al. (2018) Complex role of NK cells in regulation of oncolytic virus-bortezomib therapy. Proc Natl Acad Sci U S A 115:4927-4932
Wang, Xinmei; Kwak, Kwang Joo; Yang, Zhaogang et al. (2018) Extracellular mRNA detected by molecular beacons in tethered lipoplex nanoparticles for diagnosis of human hepatocellular carcinoma. PLoS One 13:e0198552
Callahan, Catherine L; Bonner, Matthew R; Nie, Jing et al. (2018) Lifetime exposure to ambient air pollution and methylation of tumor suppressor genes in breast tumors. Environ Res 161:418-424
Gopalakrishnan, Bhavani; Cheney, Carolyn; Mani, Rajeswaran et al. (2018) Polo-like kinase inhibitor volasertib marginally enhances the efficacy of the novel Fc-engineered anti-CD33 antibody BI 836858 in acute myeloid leukemia. Oncotarget 9:9706-9713
Hankey, William; Frankel, Wendy L; Groden, Joanna (2018) Functions of the APC tumor suppressor protein dependent and independent of canonical WNT signaling: implications for therapeutic targeting. Cancer Metastasis Rev 37:159-172
Felix, A S; Brasky, T M; Cohn, D E et al. (2018) Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer 142:1102-1115
Stover, Daniel G; Parsons, Heather A; Ha, Gavin et al. (2018) Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast Cancer. J Clin Oncol 36:543-553
Jacobsen, Paul B; DeRosa, Antonio P; Henderson, Tara O et al. (2018) Systematic Review of the Impact of Cancer Survivorship Care Plans on Health Outcomes and Health Care Delivery. J Clin Oncol 36:2088-2100

Showing the most recent 10 out of 2602 publications